Skip to content
DataLookout
Menu

ClinicalTrials.gov term: Depressive Disorder

Depression clinical trials

Get alerts when Depression trials change
Data updated daily from ClinicalTrials.gov, last refresh 2026-11-22

What changed in the last 30 days

216 trials changed in the last 30 days: 4 stopped, 97 with notable changes, 115 with minor changes only.

  1. Notable: RENEW-MDD-3 · Brenipatide · Major Depressive Disorder Recruitment opened Eli Lilly and CompanyPhase 2 NCT07928245
  2. Notable: IPSILON · Influence of a PSychological Intensive Support Program for Lung Cancer Patients ON Post-operative Outcomes Recruitment opened Fondazione Policlinico Universitario Agostino Gemelli IRCCSNot applicable NCT07260227
  3. Notable: Peripartum 40 Hz Audiovisual Stimulation on Postpartum Depression in Women Undergoing Elective Cesarean Section: A Randomized Clinical Trial Recruitment opened The First People's Hospital of LianyungangNot applicable NCT07807462
  4. Minor: HEAL-ABC · E-Mindfulness Approaches for Living After Breast Cancer Enrollment closed, study ongoing NRG OncologyPhase 3 NCT06748222
  5. Minor: Celecoxib on Neuroinflammation in MDD Sponsor refiled this as recruiting (was completed) Stony Brook UniversityPhase 4 NCT04814355
  6. Notable: ISO4SAD · ISO Principle-Based Music Intervention for Reducing Stress, Anxiety, and Depression Primary completion pushed from Aug 30, 2026 to Apr 30, 2027 Shanghai Mental Health CenterNot applicable NCT07055061
  7. Notable: ET+ · Trauma Plus Eligibility criteria changed Envisioning Justice Solutions, IncNot applicable NCT07945639
  8. Notable: Lay-Delivered Behavioral Activation in Senior Centers Results posted: Nov 19, 2026 University of WashingtonNot applicable NCT04621877
  9. Notable: ProMOOD · Adjunctive Probiotic Therapy in Major Depressive Disorder Start date pushed from Oct 2026 to Dec 2026 University MariborNot applicable NCT07786285
  10. Minor: NBI-1065845-MDD3026 · Osavampator as an Adjunctive Treatment · Major Depressive Disorder (MDD) Trial sites expanded: 35 → 39 locations Neurocrine BiosciencesPhase 3 NCT06963021
  11. Minor: NBI-1065845-MDD3025 · Osavampator as an Adjunctive Treatment · Major Depressive Disorder (MDD) Trial sites expanded: 39 → 42 locations Neurocrine BiosciencesPhase 3 NCT06911112
  12. Minor: Osavampator as an Adjunctive Treatment · Major Depressive Disorder (MDD) Trial sites expanded: 18 → 30 locations Neurocrine BiosciencesPhase 3 NCT06786624
  13. Stopped: X-NOVA2 · Azetukalner Versus Placebo in Major Depressive Disorder Trial terminated Xenon Pharmaceuticals Inc.Phase 3 NCT06775379
  14. Stopped: Electrical Vestibular Nerve Stimulation (VeNS) as a Treatment for Major Depressive Disorder (MDD) Withdrawn before enrolling Neurovalens Ltd.Not applicable NCT06470035
  15. Notable: Fixed Order, Open-Label, Dose-Escalation Study of DMT in Humans Enrollment reduced: 30 → 10 participants Yale UniversityPhase 1 NCT04711915
  16. Notable: Guided Imagery on Anxiety, Depression, and Fatigue in Patients Receiving Hemodialysis Primary endpoint(s) modified Adiyaman UniversityNot applicable NCT07938372
  17. Notable: KeDA · Ketamine for Combined Depression and Alcohol Use Disorder Primary and study completion pushed from Jul 1, 2027 to Jul 1, 2028 University Hospital of North NorwayPhase 1/2 NCT06090422
  18. Notable: POWER · Lifestyle Interventions to Prevent Cognitive Deficits · Depressive Symptoms: From Mechanisms to Clinical Practice Primary completion pushed from Aug 2026 to Apr 2027 IRCCS Centro San Giovanni di Dio FatebenefratelliNot applicable NCT07009223
  19. Notable: QoL in LSSC · Quality of Life and Functional Outcomes in Laryngeal Cancer Patients Primary completion pushed from Jan 2, 2027 to Jul 2, 2027 Saglik Bilimleri UniversitesiNot specified NCT07320820
  20. Notable: STAY · Strategic Treatment and Assessment for Youth Primary and study completion pushed from Nov 30, 2026 to Nov 30, 2027 Yale UniversityNot applicable NCT06515236
  • Stopped: terminated, suspended or withdrawn
  • Notable: the plan changed
  • Minor: routine updates

New sponsor entrants, last 90 days sponsors with their first trial in this area

First postedTrialSponsorPhase
2026-11-20 NCT07950956 A Prospective, Multicenter, Randomized, No-Treatment Controlled, Evaluator-Blinded… Fiman (Changchun) Pharmaceutical Biotechnology Company Limited new
2026-11-20 NCT07950800 From There Towards Now; Intervention for Jewish and Indonesian Post-war Generations Arkin new
2026-11-19 NCT07948603 Comparing Brief, Low-Intensity Self-Improvement Exercises in a Non-Clinical Population Spark Wave, LLC new
2026-11-19 NCT07949500 Esketamine Plus Sirolimus for Adults With Depression Who Have Not Responded to Esketamine Rodolfo Furlan Damiano new Phase 2
2026-11-18 NCT07946484 Acupuncture for Depression: Sigma-1 Receptor-Related Brain Network Modulation Shenzhen Hospital of Guangzhou University of Chinese Medicine new
2026-11-17 NCT07943936 Anxiety Reduction, Learning Support, Mood, and Self-efficacy Adaptation in Families With… Hospital Universitario 12 de Octubre new
2026-11-17 NCT07941986 Association Between Maternal Intrapartum Pethidine Exposure and Respiratory Depression in… Egyptian Chinese University new
2026-11-17 NCT07942454 The Effects of Prayer on Psychological, Physical, and Spiritual Well-being in Adults With… Patricia Kaufman new
2026-11-16 NCT07938372 Effect of Guided Imagery on Anxiety, Depression, and Fatigue in Patients Receiving… Adiyaman University new
2026-11-13 NCT07935096 Effect of Nature-based Interventions on Mental Health and Markers of Inflammation in… Instituto Nacional de Salud, Colombia new

Active trials by phase

Early Phase 1
18
Phase 1
40
Phase 1/2
27
Phase 2
158
Phase 2/3
17
Phase 3
71
Phase 4
80
Not charted: 1,827 active trials with no phase listed on ClinicalTrials.gov (typically behavioural, device, procedure and observational studies).
Get alerts when Depression trials change
Status changes, date slips, and new sponsor entrants: detected daily, delivered to your inbox.
Start monitoring free

Narrower conditions

Active trials